Literature DB >> 27986919

Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.

Dong Hyun Nam1, Kuili Fang1, Carlos Rodriguez1, Tyler Lopez1, Xin Ge2.   

Abstract

Matrix metalloproteinase-14 (MMP-14) plays important roles in cancer metastasis, and the failures of broad-spectrum MMP compound inhibitors in clinical trials suggested selectivity is critical. By grafting an MMP-14 specific inhibition motif into complementarity determining region (CDR)-H3 of antibody scaffolds and optimizing other CDRs and the sequences that flank CDR-H3, we isolated a Fab 1F8 showing a binding affinity of 8.3 nM with >1000-fold enhancement on inhibition potency compared to the peptide inhibitor. Yeast surface display and fluorescence-activated cell sorting results indicated that 1F8 was highly selective to MMP-14 and competed with TIMP-2 on binding to the catalytic domain of MMP-14. Converting a low-affinity peptide inhibitor into a high potency antibody, the described methods can be used to develop other inhibitory antibodies of therapeutic significance.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CDR grafting; inhibitory antibody; matrix metalloproteinase; phage display; synthetic library

Mesh:

Substances:

Year:  2016        PMID: 27986919      PMCID: PMC6283398          DOI: 10.1093/protein/gzw070

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  35 in total

1.  A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.

Authors:  Weisong Qin; Jiannan Feng; Yan Li; Zhou Lin; Beifen Shen
Journal:  Mol Immunol       Date:  2006-11-27       Impact factor: 4.407

Review 2.  Matrix metalloproteinase proteomics: substrates, targets, and therapy.

Authors:  Charlotte J Morrison; Georgina S Butler; David Rodríguez; Christopher M Overall
Journal:  Curr Opin Cell Biol       Date:  2009-07-16       Impact factor: 8.382

3.  Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.

Authors:  Yong Zhang; Huafei Zou; Ying Wang; Dawna Caballero; Jose Gonzalez; Elizabeth Chao; Gus Welzel; Weijun Shen; Danling Wang; Peter G Schultz; Feng Wang
Journal:  Angew Chem Int Ed Engl       Date:  2014-12-29       Impact factor: 15.336

4.  The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations.

Authors:  G S Butler; M Hutton; B A Wattam; R A Williamson; V Knäuper; F Willenbrock; G Murphy
Journal:  J Biol Chem       Date:  1999-07-16       Impact factor: 5.157

5.  Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

Authors:  Eleanor I Ager; Sergey V Kozin; Nathaniel D Kirkpatrick; Giorgio Seano; David P Kodack; Vasileios Askoxylakis; Yuhui Huang; Shom Goel; Matija Snuderl; Alona Muzikansky; Dianne M Finkelstein; Daniel T Dransfield; Laetitia Devy; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  J Natl Cancer Inst       Date:  2015-02-20       Impact factor: 13.506

6.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

7.  Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?

Authors:  Stanley Zucker; Jian Cao
Journal:  Cancer Biol Ther       Date:  2009-12-19       Impact factor: 4.742

8.  Structural insight into distinct mechanisms of protease inhibition by antibodies.

Authors:  Yan Wu; Charles Eigenbrot; Wei-Ching Liang; Scott Stawicki; Steven Shia; Bin Fan; Rajkumar Ganesan; Michael T Lipari; Daniel Kirchhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-05       Impact factor: 11.205

9.  A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth.

Authors:  Juho Suojanen; Tuula Salo; Erkki Koivunen; Timo Sorsa; Emma Pirilä
Journal:  Cancer Biol Ther       Date:  2009-12-19       Impact factor: 4.742

10.  SAbPred: a structure-based antibody prediction server.

Authors:  James Dunbar; Konrad Krawczyk; Jinwoo Leem; Claire Marks; Jaroslaw Nowak; Cristian Regep; Guy Georges; Sebastian Kelm; Bojana Popovic; Charlotte M Deane
Journal:  Nucleic Acids Res       Date:  2016-04-29       Impact factor: 16.971

View more
  8 in total

1.  Reducing proteolytic liability of a MMP-14 inhibitory antibody by site-saturation mutagenesis.

Authors:  Ki Baek Lee; Zachary Dunn; Xin Ge
Journal:  Protein Sci       Date:  2019-01-11       Impact factor: 6.725

2.  Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies.

Authors:  Tyler Lopez; Chen Chuan; Aaron Ramirez; Kuan-Hui E Chen; Mary Y Lorenson; Chris Benitez; Zahid Mustafa; Henry Pham; Ramon Sanchez; Ameae M Walker; Xin Ge
Journal:  Biotechnol Bioeng       Date:  2018-09-15       Impact factor: 4.530

Review 3.  Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.

Authors:  Evette S Radisky; Maryam Raeeszadeh-Sarmazdeh; Derek C Radisky
Journal:  J Cell Biochem       Date:  2017-07-17       Impact factor: 4.429

Review 4.  Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.

Authors:  Gregg B Fields
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 5.  The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.

Authors:  Gregg B Fields
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

Review 6.  Combined Radiochemotherapy: Metalloproteinases Revisited.

Authors:  Verena Waller; Martin Pruschy
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 7.  Monoclonal antibodies against metzincin targets.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

Review 8.  Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics.

Authors:  Maryam Raeeszadeh-Sarmazdeh; Linh D Do; Brianne G Hritz
Journal:  Cells       Date:  2020-05-25       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.